Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients. - Wikidata - wikimedia - TriplyDB

Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients.

Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients.

http://www.wikidata.org/entity/Q34743196

about

Amyloidosis in Retinal Neurodegenerative Diseases Visual and Ocular Manifestations of Alzheimer's Disease and Their Use as Biomarkers for Diagnosis and Progression The Eye As a Biomarker for Alzheimer's Disease Ocular indicators of Alzheimer's: exploring disease in the retina Retinal macroglia changes in a triple transgenic mouse model of Alzheimer's disease.Alzheimer's Disease-Related Protein Expression in the Retina of Octodon degus A test of lens opacity as an indicator of preclinical Alzheimer Disease.Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects.Tau-Driven Neuronal and Neurotrophic Dysfunction in a Mouse Model of Early Tauopathy.Changes to the lateral geniculate nucleus in Alzheimer's disease but not dementia with Lewy bodies.Nonvascular retinal imaging markers of preclinical Alzheimer's disease.Amyloid Plaques in Retina for Diagnosis in Alzheimer's Patients: a Meta-Analysis.Promise and challenge: the lens model as a biomarker for early diagnosis of Alzheimer's disease.Retinal manifestations of Alzheimer's disease.Alpha-synuclein modulates retinal iron homeostasis by facilitating the uptake of transferrin-bound iron: Implications for visual manifestations of Parkinson's disease.Optical coherence tomography angiography: an overview of the technology and an assessment of applications for clinical research.Visual system manifestations of Alzheimer's disease.Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease.Emerging ocular biomarkers of Alzheimer disease.Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease.Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.Investigations into Retinal Pathology in the Early Stages of a Mouse Model of Alzheimer's Disease.α-Synuclein impairs ferritinophagy in the retinal pigment epithelium: Implications for retinal iron dyshomeostasis in Parkinson's disease.Absence of Alzheimer Disease Neuropathologic Changes in Eyes of Subjects With Alzheimer Disease.Specific patterns of neuronal loss in the pulvinar nucleus in dementia with lewy bodies.Can the lens model provide a biomarker for Alzheimer's disease?Effect of curcumin on amyloid-like aggregates generated from methionine-oxidized apolipoprotein A-I.Reduced contrast sensitivity among older women is associated with increased risk of cognitive impairment.In vivo imaging of retinal neurodegeneration at the single cell level in humans.Revolution of Alzheimer Precision Neurology Passageway of Systems Biology and Neurophysiology.Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain.Visual Features in Alzheimer's Disease: From Basic Mechanisms to Clinical Overview Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer's disease brains: Implications for in-vivo diagnostics

P2860

Q26739839-84527ECF-A0E7-41FD-BA6C-29010F666D95 Q26752621-0D8AC81C-0765-4A88-844C-25EC078129AF Q28070142-905870F5-709C-4A72-8992-A69C6BC5AD6B Q28078670-4E687D89-D76A-4257-BAD9-C22203F341E7 Q34245979-237A66D0-6182-4F34-9116-E989916BBE5B Q35743990-86365AEA-5937-4DB3-AE43-35EA3EC52466 Q36055299-762374B1-6323-4E39-911B-733AEB6BEED7 Q36115621-737C1746-0101-4EEB-B30A-6101F9AC65EA Q36587120-0E307D58-6856-46BD-9ED7-5D464C95573B Q37020745-A2059526-8268-4CE3-A4FB-48DC427CA4D1 Q37363628-1A065F01-C1B6-4C6B-8C1D-4B6A2FA1A3A6 Q37405016-F70B70C1-74DB-4C01-B4C8-46FE598D9B54 Q37622009-7EF2EB6C-208F-41ED-9A8E-96B0668EBBDB Q38237224-A2216BD6-8140-48E8-B7F7-40DA98C00BFD Q38762283-D47BE00F-DE5A-4BE4-B6BF-95F661BC1E5B Q38814500-D2C66B49-A683-4659-B7D2-43E96B121890 Q39013852-BD9FD731-1F40-4612-8D9A-15D63AF2B2ED Q39091275-B6B9ED40-62DE-4ABC-BF8D-8CA7D54E7928 Q39113804-F016071D-3F84-48B1-AEB4-09F52C111673 Q41845723-DFD62E85-20C5-4EA2-BDB1-832653737413 Q42095746-B38BC416-5100-4875-9563-83A92DB060E0 Q42327572-0E07851A-4949-4B39-B767-5C6941B7F4CC Q42373959-8927ECE8-CE2F-4D93-ADC3-5CDF2772A3D3 Q48229261-7E6B4642-9E77-4FA1-9A89-7821392DDC7A Q48370104-BCC7EAD7-30D3-4F20-AC2D-BF7AD3481B03 Q48939586-33CF4C69-FF4F-4842-A17C-40997B5BE991 Q50045718-2E4E96EF-7F2B-497C-A716-C7A84F3FC608 Q50531828-8C86EE32-4FF1-43CB-9A7A-FF3C10D3530F Q50977365-E3A5B568-1007-4220-8465-930884752D7E Q51760905-6522D20E-F4E4-4CE3-B7A8-8077CAC8075F Q53398002-C4A186D6-DA40-494E-A7C5-56D78BFD5156 Q58567916-A901DF9D-7398-4839-A81B-025ACE8DBE27 Q58794529-36464EFE-8FA5-4577-9574-6A5716BE05C6

P2860

Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients.

http://www.wikidata.org/entity/Q34743196

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Beta-amyloid, phospho-tau and ...... Parkinson's disease patients.

@ast

Beta-amyloid, phospho-tau and ...... Parkinson's disease patients.

@en

Beta-amyloid, phospho-tau and ...... Parkinson's disease patients.

@nl

type

label

Beta-amyloid, phospho-tau and ...... Parkinson's disease patients.

@ast

Beta-amyloid, phospho-tau and ...... Parkinson's disease patients.

@en

Beta-amyloid, phospho-tau and ...... Parkinson's disease patients.

@nl

prefLabel

Beta-amyloid, phospho-tau and ...... Parkinson's disease patients.

@ast

Beta-amyloid, phospho-tau and ...... Parkinson's disease patients.

@en

Beta-amyloid, phospho-tau and ...... Parkinson's disease patients.

@nl

P1433

Q34743196-39B639D8-A389-433B-8007-80F849B08E9C

P1476

Q34743196-2BD4C431-AC38-4DE3-BBD0-72801EAC1E88

P2093

Q34743196-2933E333-5516-4614-A538-A48080A1F95F

Q34743196-4C791EE2-565A-476E-AB0A-53D3EEF69D82

Q34743196-6F900E22-189B-4E8C-B341-20DFD249F178

Q34743196-BA6A11C6-AB0A-470E-85D4-243C0DE222CF

P2860

Q34743196-01E43F64-7A21-4386-AD02-26086766741B

Q34743196-038F14FD-59E8-45CA-B179-7CBF15422F65

Q34743196-188AFA01-1AF9-4C7D-BA38-4B3F24FEFAD5

Q34743196-1DCB7403-EF97-452E-B4A5-5FAF177C4963

Q34743196-2D7587A3-0F7A-4A9C-BA7D-3D6605CF25C7

Q34743196-2DC75B4B-F35C-405C-9667-77A8FA6BC28C

Q34743196-348DEE39-6115-4984-9F78-84345E85C8C1

Q34743196-350868E6-6B44-4E81-8EEA-D66EC9B37516

Q34743196-4085ED1D-4881-4AB8-955F-F2E8145131E0

Q34743196-43427DF1-4C0B-4611-AB98-6C663C131A20

P304

Q34743196-FA28E0CF-EC12-42D7-827B-3D34A08A9D99

P31

Q34743196-22308C1B-8DE3-4BB1-AC4F-412B20CA7B8E

P356

Q34743196-2FF9F43C-BF77-4327-AFD6-FB7C774FB1F8

P433

Q34743196-30F643DE-95BD-4FC7-BDD5-2B1D2EA27F3F

P478

Q34743196-513DB98E-46DB-47E7-8E26-CB63B4827170

P50

Q34743196-A46DC3F9-DD73-4528-B8A5-049910A02D17

P577

Q34743196-AB93D221-2311-4883-A7ED-261EC6018FC1

P5875

Q34743196-B2FADFF3-FA56-4969-8316-313E0D03A123

P698

Q34743196-081FB98B-D3A7-4880-A705-68F393537CCE

P921

Q34743196-58FF7470-83B9-4A96-BA6B-71756DB3E6DB

Q34743196-87F1742E-7FEF-42A4-BB2C-5071CE4718EA

Q34743196-C9D8D26F-05CF-48C7-8CBF-D3864A41AFEE

P932

Q34743196-324E0480-1B73-45DB-A455-42CC0EA6B0DB

P356

P1433

Brain Pathology

P1476

Beta-amyloid, phospho-tau and ...... Parkinson's disease patients.

@en

P2093

Cheng-Ying Ho

http://www.w3.org/2001/XMLSchema#string

David Knox

http://www.w3.org/2001/XMLSchema#string

Juan C Troncoso

http://www.w3.org/2001/XMLSchema#string

Walter Stark

http://www.w3.org/2001/XMLSchema#string

P2860

Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome

Towards a Pharmacophore for Amyloid

Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease

Clinical amyloid imaging in Alzheimer's disease.

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease.

Pathologic lesions in neurodegenerative diseases.

Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model.

Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice.

Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

P304

25-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BPA.12070

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Charles G Eberhart

P577

2013-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236956640

http://www.w3.org/2001/XMLSchema#string

P698

23714377

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3976129

http://www.w3.org/2001/XMLSchema#string